HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery.

Abstract
To date, there is limited data on levels of platelet inhibition achieved in patients with ST-elevation myocardial infarction (STEMI) who are loaded with clopidogrel and aspirin (ASA) prior to undergoing primary percutaneous coronary intervention (P-PCI). The aim of this investigation was to evaluate the percentage of STEMI patients with high on-treatment platelet reactivity (HPR) to clopidogrel at the time of initiating P-PCI and its association with the initial patency of the infarct-related artery (IRA). This prospective pharmacodynamic study included 50 STEMI patients, previously naïve to oral antiplatelet agents, who received 500-mg ASA and 600-mg clopidogrel loading doses prior to P-PCI. Platelet function assessment was performed at the beginning of the procedure using various assays, including VerifyNow™ system (primary endpoint), light transmission aggregometry and multiple electrode aggregometry. The percentage of patients with suboptimal response to clopidogrel and ASA assessed with the VerifyNow™ system was 88.0% and 28.6%, respectively. Similar results were obtained with the other assays used. A higher percentage of patients with initial patency of the IRA was observed among those patients without HPR compared with those with HPR to clopidogrel (66.7% vs 15.9%; p=0.013), while no differences were observed regarding postprocedural angiographic or electrocardiographic outcomes. In conclusion, this study shows that a high percentage of STEMI patients have inadequate levels of clopidogrel-induced and, to a lesser extent, aspirin-mediated platelet inhibition when starting a P-PCI procedure, and suggests that a poor response to clopidogrel might be associated with impaired initial TIMI flow in the IRA.
AuthorsJosé Luis Ferreiro, Sílvia Homs, Javier Berdejo, Gerard Roura, Josep Gómez-Lara, Rafael Romaguera, Luis Teruel, Guillermo Sánchez-Elvira, Ana Lucrecia Marcano, Joan Antoni Gómez-Hospital, Dominick J Angiolillo, Ángel Cequier
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 110 Issue 1 Pg. 110-7 (Jul 2013) ISSN: 2567-689X [Electronic] Germany
PMID23615769 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
Topics
  • Arteries (pathology, surgery)
  • Clopidogrel
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (therapy)
  • Percutaneous Coronary Intervention (methods)
  • Platelet Activation (drug effects)
  • Platelet Aggregation Inhibitors (administration & dosage)
  • Preoperative Care
  • Prevalence
  • Prospective Studies
  • Ticlopidine (administration & dosage, analogs & derivatives)
  • Vascular Patency (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: